# A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

Study · id `cardio:ct-nct04255238` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04255238](<https://clinicaltrials.gov/study/NCT04255238>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04255238

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 468 participants.

## Technical summary

Registry record NCT04255238. Randomized; double masking; primary purpose treatment. Start 2020-06-30 (anticipated); primary completion 2022-05-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 468 participants (planned count; ClinicalTrials.gov record NCT04255238, source copy `cardio:ctgov-nct04255238-2020-02-19`, retrieved 2026-10-26)
- Planned start: 2020-06-30 (anticipated) (ClinicalTrials.gov record NCT04255238, source copy `cardio:ctgov-nct04255238-2020-02-19`, retrieved 2026-10-26)
- Primary completion: 2022-05-30 (anticipated) (ClinicalTrials.gov record NCT04255238, source copy `cardio:ctgov-nct04255238-2020-02-19`, retrieved 2026-10-26)
- Completion: 2022-12-30 (anticipated) (ClinicalTrials.gov record NCT04255238, source copy `cardio:ctgov-nct04255238-2020-02-19`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04255238-2020-02-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Gemigliptin 50mg
- Intervention (Drug): Dapagliflozin 10mg
- Lead sponsor: LG Chem
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: fcf877d0e369954115a9a8b659849de11a578c3441ad71e1a6b055cdfc38dfed
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
